Results 101 to 110 of about 36,503 (286)

Importância prognóstica do alelo CYP2C19*2 após uma síndrome coronária aguda: dados de um centro nacional [PDF]

, 2012
BACKGROUND: Clopidogrel requires oxidation dependent on the cytochrome P450 enzyme 2C19 (CYP2C19) to form its active metabolite. The importance of loss-of-function alleles (particularly CYP2C19*2, 681G>A) in poor platelet response to clopidogrel is well ...
Ferreira, MJ, Freitas, M, Gonçalves, F, Lourenço, M, Marques, G, Monteiro, P, Monteiro, S, Pego, J, Providência, LA, Reboredo, A, Ribeiro, G, Tavares, C, Teixeira, R   +12 more
core  

Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice [PDF]

, 2019
Epoxy-fatty-acids (EpFAs), cytochrome P450 dependent arachidonic acid derivatives, have been suggested to have anti-inflammatory properties, though their effects on autoimmune diseases like systemic lupus erythematosus (SLE) have yet to be investigated ...
Dragun, Duska, Enghard, Philipp, Gollasch, Maik, Hammock, Bruce D., Klocke, Jan, Riemekasten, Gabriela, Rudolph, Birgit, Schunck, Wolf-Hagen, Ulu, Arzu, Wu, Kaiyin   +9 more
core   +2 more sources

CYP2C19 Loss‐of‐Function Is an Independent Risk Factor of Coronary Artery Disease in Patients With Hypertension

Journal of Clinical Laboratory Analysis, EarlyView.
The relationship between Cytochrome P450 2C19 (CYP2C19) polymorphisms and coronary artery disease (CAD) in hypertensive patients was analyzed. CYP2C19 loss‐of‐function, BMI ≥ 24.0 kg/m2, and history of alcoholism were independent risk factors for CAD in hypertensive patients.
Guoliang Wei, Bin Li, Hao Wang, Wenhao Chen, Kehui Chen, Weihong Wang, Shen Wang, Hui Zeng, Yuanliang Liu, Yue Zeng, Hui Rao   +10 more
wiley   +1 more source

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj  

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fezolinetant is a non‐hormonal, selective neurokinin 3 receptor antagonist approved in multiple countries including the United States, in Europe, and in Asia for the treatment of moderate to severe vasomotor symptoms in menopausal women. Fezolinetant is primarily metabolized by CYP1A2 and was found to be a sensitive substrate for CYP1A2 ...
Mary P. Choules, Yukio Otsuka, Jace C. Nielsen, Megumi Iwai, Peter L. Bonate   +4 more
wiley   +1 more source

Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study [PDF]

, 2017
Background: The measurement of platelet reactivity in patients with stroke undergoing antiplatelet therapies is not commonly performed in clinical practice.
Bigliardi, Guido, Dell'Acqua, Maria Luisa, FERRARO, Diana, Lelli, Nicoletta, Mimmi, Stefano, NICHELLI, Paolo Frigio, Pentore, Roberta, Picchetto, Livio, Rosafio, Francesca, Trenti, Tommaso, Vandelli, Laura, Zini, Andrea   +11 more
core   +1 more source

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Polymorphic drug metabolising enzymes:Assessment of activities by phenotyping and genotyping in clinical pharmacology [PDF]

, 2001
Drug effects (pharmacodynamics) are determined by drug concentration at target site and the affinity of the drug for a target. Pharmacogenetics describes inherited differences in drug metabolising enzyme activities and differences in drug transporters ...
Tamminga, Willem Jan
core   +2 more sources

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, EarlyView.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

Pharmacogenomics and Personalized Medicine, 2018
Natalia P Denisenko,1–3 Dmitriy A Sychev,2 Zhanna M Sizova,3 Valeriy V Smirnov,4,5 Kristina A Ryzhikova,1 Zhannet A Sozaeva,1 Elena A Grishina1 1Research Center, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare ...
Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA   +6 more
doaj